Alira Health’s Transformation Talks: Real-World Evidence Strategy Playbook

Published on:
April 15, 2022

Medical and healthcare data have been gathered through various channels over the last twenty years, and with recent innovations, it offers new opportunities, becoming a crucial factor in market access strategies and clinical research. In this episode of Alira Health‘s Transformation Talks, our host Kenny Carberry, Director of Clinical Development at Alira Health, and Romain Finas, Vice President of Real-World Evidence at Alira Health, will discuss how industry stakeholders can leverage RWD to be more efficient, cost-effective, and thus increase their benefits without compromising quality.

Listen to this podcast to discover how industry stakeholders may use RWD to be more efficient, cost-effective, and maximize their benefits without sacrificing data quality and why the role of patients as an essential aspect of data gathering and sourcing cannot be overlooked when considering RWE.

Meet our speakers:

Romain Finas – Vice President, Real-World Evidence, Alira Health

Romain Finas has been building the Real-World Evidence practice for AliraHealth since mid-2020. Before AliraHealth, Romain designed and implemented the“beyond the pill” strategy for MSD France. He started living labs to test and assess innovations based on real-time data routinely collected by practitioners, among other initiatives. Romain has 20 years of experience in consultancy, healthcare, and digital.

Meet our host:

Kenny Carberry – Director, Clinical Development, Alira Health

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers various indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle, from generating a comprehensive strategy to executing a successful trial.


Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Publications July 11, 2023
Five Years Evolution of Chemotherapy Administration in Home Care in France
Have a look at the poster to get an overview of the dynamics in the development of chemotherapy in home care across different French regions during a five-year period.
Clinical France Outcomes Research
Events June 20, 2023
Advanced Wound Care Summit
We are pleased to announce that we will sponsor, attend, and speak at Advanced Wound Care Summit.
Clinical Clinical Trials Wound Healing
Events June 13, 2023
DSVR 2023
We are excited to share that we will be attending the DSVR 2023 - 15° Colloque Données de Santé en Vie Réelle.
France Real-World Evidence (RWE)
Blog May 4, 2023
How to Leverage Real-World Evidence to Achieve Orphan Drug Designation
Obtaining an orphan drug designation (ODD) is challenging and may require sponsors to leverage real-world evidence (RWE). Read the article to learn what ODD is, why it matters, and how RWE can help.
Orphan Drug Rare Disease Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.